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Background: Although Argonaute proteins are considered to play important roles in stem cell self-renewal, RNA
interference (RNAi) and translational regulation, relatively little is known about their functions in human disease. In
this study, we investigated the expression of eight members of human Argonaute family in colon cancer and
identified their potential roles in tumor development and progression.
Methods: Antibodies against human Argonaute proteins were prepared by immunizing rabbits with synthetic
peptides derived from the sequences of Argonaute members. Then we constructed a tissue microarray containing
75 specimens from colon cancer and 75 specimens from adjacent non-cancer tissue, and assayed eight different
proteins (EIF2C1, EIF2C2, EIF2C3, EIF2C4, PIWIL1, PIWIL2, PIWIL3 and PIWIL4) by immunohistochemistry on
consecutive formalin-fixed tissue microarray sections.
Results: The expression of EIF2C1-4 and PIWIL1-4 was significantly higher in tumorous tissue than in adjacent
tissue. Notably, a significant correlation was observed between the positive expression of EIF2C2, EIF2C3, EIF2C4,
PIWIL4 and the presence of distant metastasis. Logistic regression analysis revealed that an increased expression of
EIF2C1 and PIWIL2 was significantly associated with occurrence of colon cancer tissue compared with non-cancer
tissue.
Conclusions: Argonaute proteins are overexpressed in colon cancer relative to adjacent non-cancer tissue. The
expression of EIF2C2-4 and PIWIL4 appears increased in advanced tumors with distant metastasis, suggesting it
may promote tumor invasion. Furthermore, EIF2C1 and PIWIL2 might represent novel colon cancer markers with
early diagnostic significance.
Background
Colon cancer is one of the most frequent and lethal
malignancies worldwide, and the 5-year survival rate is
less than 50% [1,2]. Given the high level in incidence
rate and mortality rate of colon cancer, it would be
important to better understand the biological basis of
tumor development and progression, to develop markers
for assessing onset or prediction of therapy outcome, as
well as to identify targets for the development of novel
therapies. Colon cancer may be considered the final step
of a progressive imbalance between mucosal cell prolif-
eration and apoptosis due to the activation of oncogenes
and the inactivation of tumor suppressor genes [3-5].
The evaluation of the clinical utility of each of these
genes would require multiple consecutive experiments
with hundreds of tumor specimens. This would be both
time-consuming as well as impractical for more than a
handful of genes. Microarray technology provides a new
and promising tool that allows the detection of a large
variety of parameters simultaneously, and will be of
importance in the fight against colon cancer.
Argonaute proteins are present in all RNA-induced
silencing complexes (RISC) reported to date and are
now the best defined protein component of the RNA
interference (RNAi) machinery [6]. Humans have eight
Argonaute-like proteins, four of which fall into the
eIF2C/AGO subfamily (EIF2C1/hAGO1, EIF2C2/
hAGO2, EIF2C3/hAGO3, and EIF2C4/hAGO4) while
the remainders are the PIWI subfamily (PIWIL1/HIWI,
PIWIL2/HILI, PIWIL3, and PIWIL4/HIWI2) [7]. The
AGO subfamily is present in animals, plants, and fission
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RNAs (siRNAs) and/or microRNAs (miRNAs) as
sequence specific guides in both transcriptional and post-
transcriptional silencing mechanisms [8]. It is postulated
that eIF2C proteins might have regulatory functions in
cancer stem cell self-renewal through the RNA-mediated
gene silencing mechanism as a component of RISC. In
contrast to the AGO subfamily, the PIWI subfamily has
been identified only in animals. The PIWI subfamily
genes are expressed mainly in germ cells, whereas AGO
subfamily genes are ubiquitously expressed. Consistent
with their expression patterns, PIWI proteins may parti-
cipate in germ cell proliferation and their overexpression
may cause germ cell malignancy development [9].
Although Argonaute proteins are considered to play
important roles in RNA interference, stem cell self-
renewal and translational regulation, relatively little is
known about their functions in human disease. In the
present study, we constructe dat i s s u em i c r o a r r a yc o n -
taining 150 specimens from adjacent non-cancer tissue
and colon cancer tissue and assayed the expression of
eight members of human Argonaute family by immuno-
histochemistry on consecutive formalin-fixed tissue
microarray sections. The aim was to obtain a comprehen-
sive survey of the expression of Argonaute proteins in
colon cancer and identify their potential roles in tumor
development and progression.
Methods
Patients and colonic specimens
We selected 75 patients with colon cancer who under-
went surgery at hospitals that cooperated with Shanghai
Outdo Biotech Co., Ltd. during 2005-2007. They were
38 men and 37 women, ranging from 25 to 85 years of
age (median: 57 years). Clinicopathaological characteris-
tics of the research subjects are shown in Table 1. Paraf-
fin-embedded diagnostic tumor biopsy specimens and
their adjacent non-tumor specimens (≤ 1.5 cm away
from the tumor) were collected before any treatment.
Patients were only included in the study if they had
provided written consent to participate in the study
after receiving oral and written information regarding its
course and purpose. Approval for the study was received
from the Ethics Committee of the host institution.
Preparation of antibodies against Argonaute proteins
The optimal peptide immunogens for preparation of
antibodies against human Argonaute proteins were
selected by an in-house peptide selection database called
Antibody Designer, and then synthesized and fractio-
nated by C-Strong Corporation (Shanghai, China). The
amino acid sequences for each peptide antigen are
collected in Table 2. The synthetic peptide antigens
(KLH-coupled) were used to raise polyclonal antibodies
in rabbits as described by Pastor-Navarro N et al. [10].
Evolution of the antibody titer was controlled by mea-
suring the binding of serial dilutions of the antisera to
microtiter plates coated with peptide antigen. Eight
weeks after the first injection, sera were collected and
used to prepare purified antibodies. The IgG solution
was fractionated from the rabbit antisera by precipita-
tion with 40% saturated ammonium sulphate and then
affinity-purified on peptide affinity columns. The flow-
through was collected and stored at -20°C for the use of
Table 1 Clinicopathaological characteristics of colon
cancer cases
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Page 2 of 8ELISA, Western blot, and immunohistochemistry
analyses.
Tissue microarray construction
The colonic tissue microarray was constructed as
described previously [11]. Briefly, a tissue arraying
instrument (Beecher Instruments, Silver Spring, MD)
was used to create holes in a recipient paraffin block
and to acquire tissue cores from the donor block by a
thin-walled needle with an inner diameter of 1.5 mm,
held in an X-Y precision guide. The cylindrical sample
from the selected region in the donor block was
extruded directly into the recipient block with defined
array coordinates. After construction of the array
block, multiple 5-μm sections were cut with a micro-
tome and placed on polylysine-coated slides. The tissue
array block contained 150 samples, including 75
tumorous specimens and 75 adjacent non-tumorous
specimens.
Immunohistochemistry
Immunohistochemical staining was performed using
two-step method. The sections were deparaffinized and
rehydrated. Antigen retrieval was performed by auto-
claving the slides in 10 mM citric acid buffer. Antibo-
dies against Argonaute proteins (dilution of 1:100), and
goat anti-rabbit immunoglobulin/HRP from DAKO
were selected as primary antibody and secondary anti-
body. Reaction products were visualized with diamino-
benzidine as the chromogen and finally counterstained
with haematoxylin.
The immunohistochemical expression of each marker
was examined by light microscopy through calculating
1000 cells per 5 sights and evaluating the average num-
ber. The percentage of positive cells, as the extent of
immunostaining, was quantified under microscope and
classified into five groups. 0: < 5% positive cells; 1: 5%
to 24% positive cells; 2: 25% to 49% positive cells; 3:
50% to 74% positive cells and 4: ≥ 75% positive cells.
Intensity was scored as 0 for absence of staining, 1 for
weak, 2 for moderate, and 3 for strong staining. The
score of the intensity plus the percentage of positive
staining was used to define expression levels. 0-1: nega-
tive; 2-3: little positive (+1); 4-5: moderately positive
(+2); 6-7: strongly positive (+3).
Statistical analysis
The differential expression of Argonaute proteins
between tumorous tissue and non-tumorous tissue was
determined by Mann-Whitney U-test. Relationships
between clinicopathological and molecular parameters
were statistically analyzed using Spearman’s rank corre-
lation coefficient. The influence of each variable on
histotype of colonic lesion was assessed by logistic
regression analysis. A value of P < 0.05 was considered
to be statistically significant.
Results
Production and validation of antibodies against
Argonauteproteins
An in-house peptide selection database called Antibody
Designer was used to select optimal peptide immuno-
gens for production of antibodies against human Argo-
naute proteins. For each protein, a synthetic peptide
derived from the sequence of Argonaute member was
conjugated to KLH for immunization. All peptides
showed strong immune responses after 4 immunizations
in rabbits, and antisera exhibited high titers when tested
by ELISA using immobilized peptides on 96-well micro-
titer plates. Antibodies from individual rabbits were pur-
ified separately by peptide affinity chromatography.
Typically 2-20 milligrams of purified antibodies were
obtained for each peptide. SDS-PAGE analysis showed
that the molecular mass of purified antibodies was
50 kDa, which corresponded to the molecular mass of
rabbit IgG. Total protein extracted from either Hela or
293 cells was used for immunoblotting with purified
antibodies. Western blot analysis showed that these
purified antibodies recognized the bands at expected
molecule mass corresponding to each Argonaute mem-
ber, respectively (Figure 1). In contrast, no band was
detected with preimmune rabbit serum. Furthermore,
immunohistochemical analysis showed predominantly
cytoplasmic staining in most tumorous tissues but very
weak or absent staining in normal human tissues.
Argonaute proteins expression in adjacent non-tumorous
tissue and tumorous tissue
By use of a large tissue microarray (150 cores) we inves-
tigated the protein expression of EIF2C1-4 and PIWIL1-
4 in colon cancer specimens and adjacent non-tumorous
tissue. The tumorous or non-tumorous mucosa-specific
staining was semi-quantitatively scored by the intensity
and the percentage of positive staining. As shown in
Figure 2 and 3, Argonaute proteins expression was
detected mainly in cytoplasm of malignant cells. The
positive expression of EIF2C1 (P <0 . 0 0 1 ) ,E I F 2 C 2( P <
0.001), EIF2C3 (P <0 . 0 0 1 ) ,E I F 2 C 4( P < 0.001), PIWIL1
(P <0 . 0 0 1 ) ,P I W I L 2( P < 0.001), PIWIL3 (P < 0.001)
and PIWIL4 (P < 0.001) in tumorous tissue was signifi-
cantly higher than in adjacent non-tumorous tissue.
Images of representative immunostaining are presented
in Figure 2 and 3. The results are shown in Table 3.
Relationship between the expression of Argonaute
proteins and clinicopathological parameters
On the basis of the above results in the colon cancer
specimens, it would be interesting to evaluate the
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and clinicopathological parameters in colon cancer. As
shown in Table 4, there were no statistical differences
among each protein expression and age, sex, histological
grade, lymph node status or Duke’s stage. The positive
expression of EIF2C2 (r = 0.268, P < 0.05), EIF2C3
(r = 0.269, P < 0.05), EIF2C4 (r = 0.242, P < 0.05) and
PIWIL4 (r = 0.301, P < 0.01) in colon cancer was asso-
ciated with the presence of distant metastasis.
Logistic regression analysis of influence on histotype
ofcolonic lesion
A stepwise forward logistic regression was used to assess
the effects of EIF2C1-4 and PIWIL1-4 on histotype of
colonic lesion (whether the histotype of colonic lesion
was tumorous tissue or adjacent non-tumorous tissue).
Logistic regression analysis revealed that an increased
expression of EIF2C1 and PIWIL2 was significantly
associated with occurrence of colon cancer tissue (OR =
3.071, P = 0.005 and OR = 7.392, P < 0.001, respec-
tively) (Data are shown in Table 5). However, the rest of
human Argonaute proteins had no significant effects on
histotype of colonic lesion.
Discussion
Here, we performed a first systematic expression analy-
sis of human Argonaute proteins on a cohort of 75 Chi-
nese colon cancer specimens and subsequently
identified potential roles for Argonaute proteins in the
development and progression of colon cancer. Because
of the lack of commercially available antibodies against
Argonaute proteins, we prepared eight rabbit polyclonal
antibodies that recognized human Argonaute proteins
efficiently. With the antibodies, we detected the tissue
Figure 1 Western blot analysis of rabbit polyclonal antibodies against Argonaute proteins in Hela or 293 cell lines.( A) Total protein
extracted from Hela or 293 cells was subjected to Western blot with polyclonal antibodies against EIF2C1-4 proteins. There were the bands at
expected molecule mass corresponding to each member of AGO subfamily in the films. (B) Total protein extracted from Hela or 293 cells was
subjected to Western blot with polyclonal antibodies against PIWIL1-4 proteins. There were the bands at expected molecule mass corresponding
to each member of PIWI subfamily in the films.
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histochemistry on tissue microarray.
Although several human Argonaute proteins have
been identified, relatively little is known about their
functions in human disease. AGO subfamily members
are components essential for siRNA-mediated gene
silencing in mammalian cells and involved in the effec-
ter step of mammalian RNAi [12,13]. Recent studies
demonstrate that the human EIF2C1 gene is located on
the short arm of chromosome 1 in the region 1p34-p35.
This genomic region is frequently lost in human cancers
such as Wilms tumors, neuroblastoma, and carcinomas
of the breast, liver, and colon [14]. The human EIF2C1
gene is ubiquitously expressed at low to medium levels,
and EIF2C1 expression was found to be elevated in
Wilms tumors that lacked functional copies of the
Wilms tumor suppressor gene WT1 [14]. Together,
these findings could make human EIF2C1 an interesting
Figure 2 Immunohistochemical expression of EIF2C1, EIF2C2, EIF2C3 and EIF2C4 in colon cancer and adjacent non-cancer tissue.I n
colon cancer tissue EIF2C1-4 expression was often stronger in the cytoplasm compared with adjacent non-cancer tissue (A, B, C, D). Adjacent
non-cancer tissue is detected with very weak EIF2C1-4 expression in the cytoplasm (E, F, G, H). Magnifications: ×200.
Figure 3 Immunohistochemical expression of PIWIL1, PIWIL2, PIWIL3 and PIWIL4 in colon cancer and adjacent non-cancer tissue.I n
colon cancer tissue PIWIL1-4 expression was often stronger in the cytoplasm compared with adjacent non-cancer tissue (A, B, C, D). Adjacent
non-cancer tissue is detected with very weak PIWIL1-4 expression in the cytoplasm (E, F, G, H). Magnifications: ×200.
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development. In our study, it should be noted that posi-
tive reaction to each AGO in colon cancer tissue was
significantly higher than that in adjacent non-cancerous
tissues. The relationship of AGO subfamily with colon
cancer has not been completely elucidated. Perhaps
through RNAi-related pathways or possibly also through
distinct mechanisms, AGO subfamily members have an
important role in the progression of colon cancer.
As a subfamily of Argonaute proteins, PIWI proteins
are expressed in the germline and in somatic cells as
well [15]. Four PIWI-like proteins have been identified
in Homo sapiens. Unlike AGO subfamily proteins,
PIWI subfamily proteins do not associate with siRNAs
a n d / o rm i R N A s ,o rt h e yd os ot oal e s s e re x t e n t[ 9 ] .
Recently, it has become clear that PIWI subfamily pro-
teins bind to a third class of small RNAs called PIWI-
interacting RNAs (piRNAs) [16-19]. piRNAs and PIWIs
appear to be involved in the epigenetic control of gene
expression, the control of mRNA stability, transposon
silencing and translation regulation [6,20,21]. Elevated
expression of PIWI subfamily has been reported in sev-
eral human tumor entities. First, PIWIL1 expression has
been analysed in male germline cells, showing that
mRNA levels of PIWIL1 was upregulated in the occur-
rence of seminomas, that is, a type of testicular germ
cell tumors [22]. Liu et al. [23] showed that the percen-
tage of cells that expressed PIWIL1 increased from 10%
in normal gastric tissues to 76% in gastric cancer. In
addition, expression of the PIWIL2 protein was also
found in different tumors examined, including prostate,
breast, pancreatic, gastrointestinal, ovarian and endome-
trial cancer of human and in breast tumors, rhabdo-
myosarcoma and medulloblastoma of mouse [24]. Our
Table 3 EIF2C1-4 and PIWIL1-4 expression in adjacent
non-tumorous tissue and tumorous tissue
Marker Histotype
a Expression levels (number)
-+ 1 + 2 + 3
EIF2C1 T 1 11 48 15
N3 1 2 9 1 4 1
EIF2C2 T 1 0 30 44
N 5 32 25 13
EIF2C3 T 1 1 49 24
N 1 03 51 51 5
EIF2C4 T 0 1 38 36
N 1 43 91 01 2
PIWIL-1 T 1 4 56 14
N1 6 3 6 1 9 4
PIWIL-2 T 1 1 46 27
N2 3 3 0 2 0 2
PIWIL-3 T 3 16 47 9
N3 3 3 1 1 0 1
PIWIL-4 T 1 4 49 21
N2 3 3 4 1 1 7
aT: Tumorous tissue; N: Non-tumorous tissue.
Table 4 Relationship between the expression of Argonaute proteins and clinicopathological parameters
Marker Correlation coefficient (r)
Sex Age Duke’s stage Histologic grade LN status Distant metastasis
EIF2C1 0.074 -0.082 -0.121 -0.048 -0.001 0.130
EIF2C2 0.080 0.078 0.022 0.019 -0.163 0.268
a
EIF2C3 0.100 -0.053 0.209 0.200 0.091 0.269
a
EIF2C4 0.026 0.010 0.090 0.089 -0.116 0.242
a
PIWIL-1 0.038 0.149 0.100 -0.135 -0.024 0.205
PIWIL-2 0.123 -0.093 -0.126 -0.025 -0.087 -0.004
PIWIL-3 -0.008 0.214 0.026 -0.003 -0.097 0.146
PIWIL-4 0.014 -0.033 0.064 -0.146 -0.111 0.301
b
aP <0 . 0 5 ,
bP < 0.01, LN: lymph node.
Table 5 Logistic regression analysis of the effect of Argonaute proteins on histotype of colonic lesion
Variable Expression levels No. % Tumorous tissue Wald c
2 P OR 95% CI
EIF2C1 - 32 3.13
+1 40 27.5
+2 62 77.42
+3 16 93.75 7.723 0.005 3.071 1.392-6.777
PIWIL2 - 24 4.17
+1 31 3.23
+2 66 69.70
+3 29 93.10 14.894 0.000 7.392 2.676-20.414
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tein expression in colon cancer tissue was remarkably
higher than that in non-cancer tissue. These results
confirm the notion derived from in vitro experiments
that PIWI members might be induced by oncogenic
event [22-26]. A possible involvement of PIWI subfam-
ily in the development and progression of colon cancer
is proposed.
In order to identify markers associated with clinico-
pathological characteristics of colon cancer patients,
the relationship between sex, age, histological grade,
metastasis, Duke’s classification, and protein expression
needed additional research. Previous studies rarely
considered the clinical meaning of the presence of
AGOs and PIWIs in colon cancer. In the present
study, we found the positive correlation of EIF2C2,
EIF2C3, EIF2C4 and PIWIL4 with tumor distant
metastasis. It is suggested that EIF2C2-4 and PIWIL4
are associated with tumor progression to advanced
stage and may promote tumor invasion. However,
there were no statistical differences for each protein
expression among sex, age, histological grade and
Duke’ss t a g e .L a r g e rs t u d i e sw i t hah i g h e rn u m b e ro f
samples are necessary to confirm these results and to
identify the prognostic value of Argonaute proteins in
colon cancer.
A goal of this project is to identify biomarkers occur-
ring in colonic carcinogenesis and contributing to colon
cancer development and progression. Of the EIF2C1-4
and PIWIL1-4 analyzed by logistic regression, we
observed that an increased expression of EIF2C1 and
PIWIL2 was significantly associated with occurrence of
colon cancer tissue compared with non-cancer tissue.
This is of potential clinical importance for early diagno-
sis. The question that remains to be discussed is how
Argonaute proteins play an important role in colonic
carcinogenesis. It has been postulated that mutations or
overexpression of several Argonaute proteins might
cause cancer stem cells to unlimited self-renewal and
aberrant differentiation, resulting in a heterogeneous
population of cells [27,28]. According to the cancer
stem cells hypothesis, EIF2C1 and PIWIL2 proteins
might play a role in the balance between colonic cancer
stem cells self-renewal and division in association with
small RNAs’ pathway. A disturbance in this balance may
have strong impact on neoplastic development [26].
Coincidentally, several previous studies have reported
that the gene silencing of PIWIs by RNAi or antisense
technology inhibited the growth of cancer cells and
induced cell cycle arrest in G2/M phase in human gas-
tric cancer and seminomas [23,24], which supported the
issue that overexpression of Argonaute members was
associated with proliferation and apoptosis of cancer
stem cell.
The interaction of Argonaute proteins with small
RNAs or other part of RISC involved in carcinogenesis
has not been completely elucidated. Gene specific trans-
lational control induced by some miRNA species has
been reported to have an effect on cancer development
[29]. As a component of RISC, Argonaute proteins bind
to miRNAs or piRNAs, and aberrant regulation of these
small RNAs by Argonaute proteins might induce the
malignant phenotype of cells. SND1, also reported to be
a component of RISC, is overexpressed in human colon
cancer tissues, even in early-stage lesions [30-32]. The
relationship of SND1 with Argonaute proteins was still
unclear. Paukku et al. [30] reported that the effect of
SND1 through 3’-untranslated region of angiotensin II
type 1 receptor was independent of EIF2C2, a known
SND1 partner, and was thus RISC-independent. Identifi-
cation of target mRNA species and interacting partners
of Argonaute proteins might provide us with further
insights into more precise roles of Argonaute proteins
in colonic carcinogenesis [31].
Conclusions
In conclusion, this immunohistochemical study of tissue
microarray with 75 specimens from Chinese colon can-
cer and 75 specimens from adjacent non-tumorous tis-
sue provided the first evidence that EIF2C1-4 and
PIWIL1-4 were highly expressed in tumorous tissue
relative to non-tumorous tissue. The expression of
EIF2C2-4 and PIWIL4 appeared significantly increased
in advanced tumors with distant metastasis, suggesting
it may promote tumor invasion. Furthermore, EIF2C1
and PIWIL2 might represent novel colon cancer mar-
kers with early diagnostic significance. Taking all the
information together, we postulate that at least some
members of the human Argonaute family may be
involved in the development and progression of colon
cancer. Further study will be required to elucidate the
exact biological function of each member of Argonaute
family in human colon cancer.
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